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Background: Disabling hearing loss is a global burden. This burden is worsened by the 
emergence of multi-drug resistant tuberculosis (MDR-TB). Some of the medications used to treat 
MDR-TB are damaging to the cochlea and auditory nerve (ototoxic) and can lead to permanent hearing 
loss and/or balance disorders. Ototoxicity monitoring aims to reduce this burden by preventing or 
minimising the damage caused by ototoxic treatment as it can progress and worsen speech perception 
difficulties. However, the proposed test battery for ototoxicity monitoring is lengthy and demands 
active participation which is not ideal for ill patients (such as those on MDR-TB treatment). The 
Sensitive Range of Ototoxicity (SRO) technique is recommended to shorten the test time.  The SRO 
consists of seven consecutive relatively high frequencies determined from the highest frequency the 
participant responded to. The SRO technique is time efficient. Although the SRO technique provides 
the prospect of a shortened test battery, there is still a global lack of audiologists. Automated 
audiometry is a vital application for testing especially when audiologists are not available to physically 
do the test. Automated audiometry has been previously validated. Clinically, automated audiometry 
is objective and allows for standardisation. Even though automated audiometry helps improve access 
to monitoring more patients, patient preference is an important factor when using automated 
audiometry to ensure patient-centred care is not compromised.  
Aims and Objectives: This study aimed to investigate the specificity and sensitivity of the SRO 
technique with automated audiometry compared to the gold standard (manual audiometry). This 
comparison was made by firstly, determining the testing time efficiency and the correlation of 
thresholds obtained with the different test methods and, secondly, testing the diagnostic value of 
automated audiometry using the SRO technique. The incidence of an ototoxicity-induced hearing loss 
was described by determining the time interval between starting ototoxic MDR-TB treatment and the 
onset of a significant threshold shift (STS) according to ASHA’s criteria. Lastly, the test method 
preference of the participants with MDR-TB was described and compared using a short exit survey. 
Study Design: A prospective repeated-measures study design was used. Participants were 
chosen based on a risk factor (i.e. exposure to ototoxic medication) for an outcome of interest (i.e. 
the presence or absence of an STS). With a repeated measures study, multiple tests using different 
test methods can be compared with the same sample. 
Participants: Twenty-seven in-patients at Brooklyn Chest Hospital and DP Marais TB Hospital 
with normal hearing and on MDR-TB medication were included in the study. Their age range was from 
19 to 51 years old with an average age of 33 years old. Non-probability convenience sampling was 
used as it was cost-effective, reduced data collection time and was relatively easy to execute.  
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Data collection materials and procedures: The procedure for data collection included weekly 
follow-up testing for a maximum of four weeks. The test battery was as follows: an auditory symptom 
questionnaire, otoscopy examination, and manual and automated audiometry using the SRO 
technique with a fifteen-minute break in between. Participants were tested with the KUDUwave ™ in 
a non-sound treated room. The frequency range was determined with the SRO technique. If an STS 
was obtained, the patient was discharged from the study after completing an exit survey. 
Statistics: Analysis included descriptive statistics and inferential statistics. A Bonferroni 
corrected p-value (initially p ≤ 0.05) was used. Manual and automated audiometry thresholds were 
compared using the Pearson’s Correlation Coefficient test. Manual and automated audiometry testing 
time and threshold means were compared using paired sample’s t-tests. The diagnostic value of 
automated audiometry with the SRO technique was assessed with Receiver Operating Characteristics 
(ROC) Curves. 
Results: Manual audiometry was statistically more time-efficient compared to automated 
audiometry by an average of one minute and ten seconds (t (94) = -5.44; p< 0.003). There was a strong 
positive correlation for both left and right ears between the thresholds’ obtained from manual and 
automated audiometry at 8kHz to 16 kHz (df> 28 = r > 0.70, p< 0.003). Automated audiometry was 
found to be a fair diagnostic test (area under the curve was 0.75; p= 0.002). Also, the ROC curve 
revealed that automated audiometry had a sensitivity of 61% and specificity of 90% when compared 
to manual audiometry (gold standard). Only participants that started data collection within 31 days 
after starting their MDR-TB treatment were included in the analysis of determining the incidence of 
an ototoxicity-induced hearing loss (n= 24 ears). This study found that 41.67% of ears (n= 10) had an 
ototoxicity-induced hearing loss. A box and whisker plot revealed that data was skewed to the right 
(i.e. more variation in data between the median and the maximum values) and that the median 
number of days for an ototoxicity-induced hearing loss to appear was 33 days. Secondly, 55.55% of 
participants (n=15 out of 27) reported auditory symptoms before data collection commencement. 
Aural fullness was the most reported symptom (n= eight out of 15). Ten out of 15 (66.66%) participants 
that reported auditory symptoms obtained an ototoxicity-induced hearing loss. Lastly, most 
participants (i.e. 13 out of 19; 68.42%) that completed the exit survey had no preference between 
manual or automated audiometry. The common rationale among these participants was “No 
difference noted.” 
Conclusion: This research study has revealed that manual audiometry was more time-efficient 
compared to automated audiometry in patients with MDR-TB. Also, automated audiometry was a fair 
diagnostic test. It may aid in reducing the disproportionate audiologist to patient ratio, especially in a 
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developing country. However, manual audiometry (with the SRO technique) is more clinically 
appropriate in patients that are difficult-to-test. Secondly, audiometric settings can be changed to 
accommodate testing frequencies in 1/6 octaves so that the SRO technique can be clinically adopted. 
An ototoxicity-induced hearing loss seems to appear 33 days after ototoxic MDR-TB treatment 
commencement. Aural fullness was a commonly reported symptom among participants with MDR-
TB. Aural fullness is omnipresent in peripheral auditory pathologies. Therefore, auditory symptoms 
reported by patients’ needs a comprehensive audiological investigation. Lastly, more research is 
needed on how patients (and clinicians) experience the advances in technology innovation especially 
in audiology where technology innovation is continuously evolving. 
Keywords: Sensitive Range of Ototoxicity (SRO) technique, automated audiometry, 
ototoxicity, multi-drug resistant tuberculosis (MDR-TB), sensitivity, specificity  
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This chapter discusses the global burden of a disabling hearing loss and how the tuberculosis 
epidemic and the emergence of MDR-TB negatively affects this burden. Furthermore, the negative 
effects of MDR-TB treatment (i.e. ototoxicity) are explained. Lastly, the importance of ototoxicity 
monitoring and the ototoxicity monitoring guidelines in developing countries are reviewed. 
1.1 Burden of Disabling hearing loss & MDR TB 
There is a global burden of disabling hearing loss (Olusanya, Neumann, & Saunders, 2014). A 
hearing loss is defined as hearing thresholds worse than 25 decibel Hearing Level (dB HL) in both ears 
and a disabling hearing loss is a hearing loss in the better ear that is permanent and unaided at 40 dB 
HL or worse (World Health Organization (WHO), 2018). Globally, 5.3% of the world’s population have 
a disabling hearing loss (WHO, 2018). This burden is worse in developing countries, like South Africa 
with the Tuberculosis (TB) epidemic resulting in the increased use of ototoxic medication which 
contributes to this burden (Olusanya et al., 2014; WHO, 2018).    
The emergence of multi-drug resistant tuberculosis (MDR-TB) is the primary reason for the 
current TB epidemic (Appana, Joseph, & Paken, 2016). In a 2018 statistical report, the incidence of TB 
was 301 000 in South Africa (WHO, 2019). MDR-TB is TB strains that are resistant to first-line TB 
treatment such as rifampicin and isoniazid (Farley et al., 2011). For example, in 2016, 600 000 new 
cases of DR-TB cases were reported globally of which 490 000 were MDR-TB (WHO, 2017). Moreover, 
South Africa was reported as one of the world’s highest TB burden countries in 2019 where the 
incidence of MDR-TB was 11 000 (WHO, 2019). The emergence of MDR-TB presents a challenge in 
controlling the global TB burden as a more aggressive medication is needed to treat it (WHO, 2017).   
MDR-TB treatment options are limited (Zumla et al., 2014). Regulatory authorities have 
approved two new treatment options for MDR-TB, bedaquiline and delamanid (Zumla et al., 2014). 
South Africa has announced the availability of bedaquiline as a new treatment option for patients with 
MDR-TB that meet the criteria (e.g., patients with rifampicin-resistant TB) ("Bedaquiline roll-out," 
2018). Bedaquiline is prized for having fewer side effects (e.g., less ototoxic) compared to traditional 
injectable medication (i.e. aminoglycosides) ("Bedaquiline roll-out," 2018; Khoza-Shangase, 2017; 
WHO, 2018). Bedaquiline is a newly developed drug and its potential ototoxic effects still need to be 
tested in different contexts (Khoza-Shangase, 2017). In addition, resistance to bedaquiline is a 
possibility (Pontali, Sotgiu, D'Ambrosio, Centis, & Migliori, 2016). Aminoglycosides are one of the more 
traditional choices of treatment for MDR-TB (Zimmerman & Lahav, 2013), especially to those patients 
that do not meet the criteria to be treated with a less aggressive treatment such as bedaquiline 
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("Bedaquiline roll-out," 2018). Aminoglycosides are endorsed by WHO (Adeyemo, Oluwatosin, & 
Omotade, 2016) as cost-effective and efficient in alleviating resistant bacterial infections (Zimmerman 
& Lahav, 2013). This is especially important in developing countries where cost-effective treatment is 
an economic necessity (Zimmerman & Lahav, 2013). Although aminoglycosides are useful in treating 
MDR-TB (Sagwa et al., 2015), they are toxic to the auditory nerve and the inner ear (Zimmerman & 
Lahav, 2013). Damage to the inner ear due to medication is described as ototoxicity (Govender & 
Paken, 2015) and can cause a permanent hearing loss (Paken, Govender, Pillay, & Sewram, 2016). 
Aminoglycosides usually damage the cochlear regions necessary for hearing high-frequencies first 
then it progresses to cochlear regions necessary for hearing low-frequencies (Adeyemo et al., 2016).   
1.2 Impact of Disabling Hearing loss & MDR TB 
A permanent hearing loss has numerous negative effects on the individual and society at large 
(Adeyemo et al., 2016; Sagwa et al., 2015; WHO, 2017). A hearing loss negatively affects speech 
perception and the ability to locate a sound source (Arlinger, 2003). It also compromises (spoken) 
communication abilities in post-lingual individuals (Appana et al., 2016). All these difficulties 
negatively affect the effective communication of the individual with a hearing loss (Arlinger, 2003; 
WHO, 2018). The individual’s frequent communication partners also face the same difficulty and 
frustration (Manrique-Huarte, Calavia, Huarte Irujo, Girón, & Manrique-Rodríguez, 2016). In some 
instances, this hearing loss and its negative effects can be managed by hearing assistive devices and/or 
aural rehabilitation. However, management can be costly especially in developing countries (Sagwa et 
al., 2015; WHO, 2018).  
Besides the negative effects a hearing loss has on speech perception, a hearing loss and MDR-
TB negatively affect the individual’s quality of life and well-being (Appana et al., 2016; Sagwa et al., 
2015). When a hearing loss is not managed it leads to a decreased quality of life due to stigmatization, 
social isolation, depression, low self-esteem, etc. (Adeyemo et al., 2016; Gates & Mills, 2005; 
Manrique-Huarte et al., 2016; WHO, 2018). Individuals with MDR-TB may encounter the same 
stigmatization and psychological distress (Bauer, Leavens, & Schwartzman, 2013). Both a hearing loss 
and MDR-TB are financial burdens as individuals may have a narrower scope of employment 
opportunities (Adeyemo et al., 2016; Bauer et al., 2013). This may be due to communication difficulties 
and MDR-TB may affect how well individuals do their job (Adeyemo et al., 2016; Bauer et al., 2013). 
Having a hearing loss and MDR-TB are also financial burdens to the economy (WHO, 2018). For 
example, WHO (2017) indicated that treatment costs for TB have increased and funding demands are 
still prevalent. For example, health departments in developing countries may accept treatment 
options even though it has a less than favourable risk/benefit ratio due to affordability (Khoza-
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Shangase, 2017). WHO (2018) indicated that unaddressed hearing loss presents 750 billion 
international dollars in annual global costs. Moreover, the South African TB treatment budget for 2019 
was reported to be 240 million US dollars (WHO, 2019).  Secondly, ototoxicity causes a permanent 
irreversible hearing loss  with its own economic demands to both the individual affected and the 
government (Khoza-Shangase, 2017). For example, loss of hearing may result in loss of employment 
and secondly rehabilitation costs such as amplification and aural rehabilitation (Khoza-Shangase, 
2017). 
1.3 Ototoxicity Monitoring 
Ototoxicity monitoring provides the means to minimise the impact of hearing loss through 
early identification, which could enable early management (Khoza-Shangase, 2017). Ototoxicity 
monitoring entails regular hearing sensitivity evaluations to detect the early onset of hearing loss and 
thereby preventing it from progressing to areas important for communication but contribute to 
speech in noise perception (Paken et al., 2016). Ototoxicity monitoring helps in optimizing aural 
rehabilitation and further management (Crundwell, Gomersall, & Baguley, 2016) reducing the 
contribution to the financial burden of unaddressed hearing losses (WHO, 2018) and preserving 
quality of life (Konrad-Martin, Reavis, McMillan, Helt, & Dille, 2014). There is evidence showing the 
effectiveness of ototoxicity monitoring in preventing further ototoxic damage (Duggal & Sarkar, 2007). 
If a significant threshold shift (STS) in hearing sensitivity has been identified, the prescribed 
aminoglycoside treatment will be altered to reduce its effects on the auditory nerve and inner ear 
(Crundwell et al., 2016). According to the American Speech-Language-Hearing Association (ASHA), this 
alteration includes dosage lowering, dosage stopping and/or changing to less ototoxic medication 
(ASHA, 1994). This will be done to minimize further damage, motivate for counselling and encourage 
further management (Crundwell et al., 2016). An ototoxicity monitoring protocol is essential in 
preventing a hearing loss from becoming disabling (Govender & Paken, 2015) and, in turn, minimising 
the hearing loss’s added impact on the quality of life (of patients with MDR-TB) (Appana et al., 2016).  
Ototoxicity monitoring guidelines devised for developed countries (e.g., ASHA, 1994) provide 
a structured protocol that may not be practical for the South African context (Govender & Paken, 
2015). This impracticality is due to several reasons. Firstly, there is limited staff to execute testing 
(Govender & Paken, 2015; Konrad-Martin et al., 2014). Secondly, there is also limited appropriate 
audiological equipment (such as sound-treated rooms, sensitive audiometers, etc.) (Govender & 
Paken, 2015; Konrad-Martin et al., 2014). Both limitations in (human and equipment) resources are 
due to funding demands leading to competing health demands (von Groote, Bickenbach, & 
Gutenbrunner, 2011). There is also a lack of appropriate infection control (Govender & Paken, 2015). 
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Appropriate infection control is relevant to ototoxicity monitoring guidelines because MDR-TB is 
particularly transmissible in under-resourced healthcare facilities as seen in developing countries 
(Bock, Jensen, Miller, & Nardell, 2007). This then increases the probability of hospital staff being 
infected with MDR-TB (Von Delft et al., 2015). There is also limited funding for ototoxicity monitoring 
programs, improper referral systems and a lack of consistency among South African audiologists with 
ototoxicity monitoring protocols (Govender & Paken, 2015; Konrad-Martin et al., 2014). For example, 
there is a lack of awareness among South African audiologists about national ototoxicity monitoring 
guidelines (Govender & Paken, 2015). There are also discrepancies in the ototoxicity monitoring 
protocol used among audiologists in South Africa (Govender & Paken, 2015). These discrepancies 
include conducting baseline assessments, the interval between hearing evaluations of patients with 
MDR-TB (which vary between one-month and whenever the patient experiences symptoms) and/or 
using sensitive test methods to detect ototoxic damage (Govender & Paken, 2015). Some audiologists 
only use conventional pure tone audiometry which is not a sensitive test method to detect 
an ototoxicity-induced hearing loss (ASHA, 1994). These challenges need to be resolved for the 
successful implementation of a practical ototoxicity monitoring program in developing countries 
(Konrad-Martin et al., 2014).  
This research study aimed to determine the feasibility of using automation (i.e. automated 
audiometry) and a shortened test battery (i.e. the sensitive range of ototoxicity; SRO technique) in 
patients with MDR-TB. The objectives for this aim was to investigate the sensitivity, specificity, 
diagnostic value and time efficiency of automated audiometry with the SRO technique compared to 
manual audiometry. Secondly, the type of auditory symptoms and the time interval for a significant 
threshold shift to appear after starting MDR-TB medication were described. Lastly, the test method 
preference between automated and manual audiometry of patients on MDR-TB were explored.   
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  Literature Review  
This chapter delves deeper into the different aspects of ototoxicity monitoring, such as 
monitoring interval frequency, length and testing techniques used. It also discusses the practicality of 
ototoxicity monitoring guidelines in developing countries in detail. The short comings of developing 
countries with regards to the field of audiology is high-lighted and how new advances in technology 
aims to circumvent this. Lastly, the importance of patient-centred care is discussed. 
2.1 Ototoxicity Monitoring Hearing Evaluations  
Ototoxicity monitoring guidelines require that patients be monitored every two to three days 
or at least once every week (ASHA, 1994). This is because a significant threshold shift  (STS) in hearing 
sensitivity can occur immediately after the commencement of ototoxic medication (Sara, Teh, & 
Friedland, 2014).  De Jager and Van Altena (2002) indicated that an ototoxicity-induced hearing loss 
appears five days after ototoxic MDR-TB treatment commencement. However, conventional 
audiometry was used, which is not as sensitive as high-frequency audiometry (Durrant et al., 2009; 
Paken et al., 2016). Secondly, not all participant baseline information was available to conclude 
whether the presence of a hearing loss was due to ototoxicity and not pre-existing (De Jager & Van 
Altena, 2002). In contrast to this study, a longitudinal study by Appana et al. (2016) indicated that an 
STS in hearing sensitivity appears one month after ototoxic MDR-TB treatment commencement. 
However, participants were monitored monthly (Appana et al., 2016). Other studies indicate that the 
onset of an ototoxicity-induced hearing loss may appear post-treatment (Kolinsky, Hayashi, Karzon, 
Mao, & Hayashi, 2010). These studies demonstrate conflicting evidence for the onset of an ototoxicity-
induced hearing loss. Therefore, this research investigated the incidence of an ototoxicity-induced 
hearing loss indicated by an STS in hearing sensitivity. The time it takes for an ototoxicity-induced 
hearing loss to emerge once treatment has commenced as well as the associated symptoms 
experienced were described. This may indicate the regular intervals of hearing evaluations needed for 
the successful identification of an ototoxicity-induced hearing loss.   
2.2 Current Ototoxicity Monitoring Protocol 
The ototoxicity monitoring protocol followed in most Western Cape public health facilities, 
which is based on ASHA’s guidelines (1994), are as follows: brief case history, otoscopy examination, 
tympanometry testing, conventional and extended high-frequency air conduction pure tone 
audiometry for baseline testing (K. Gangerdine, personal communication, October, 23, 2018). Follow-
up testing procedures include otoscopy and conventional and extended high-frequency air conduction 
pure tone audiometry only (K. Gangerdine, personal communication, October, 23, 2018). If a 
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significant change in hearing has been detected during follow-up testing, tympanometry and bone 
conduction pure tone audiometry is completed during the same session (K. Gangerdine, personal 
communication, October, 23, 2018). The patient is then required to be tested every two weeks until 
hearing sensitivity stabilises (K. Gangerdine, personal communication, October, 23, 2018). If no 
change in hearing has been identified, the patient is then tested once a month (K. Gangerdine, 
personal communication, October, 23, 2018).  
The current ototoxicity monitoring protocol is comprehensive and lengthy (Konrad-Martin, 
2014). Patients taking aminoglycosides may not be able to concentrate for long periods of time during 
audiological testing (Paken et al., 2016). Aminoglycosides strain the body due to their negative side 
effects such as nausea, vomiting, anorexia, etc. (Schacht, Talaska, & Rybak, 2012). It takes 
approximately eight minutes to do conventional audiometry testing excluding other audiological tests 
such as otoscopy, immittance testing, speech audiometry and extended-high frequency audiometry 
(Swanepoel, Mngemane, Molemong, Mkwanazi, & Tutshini, 2010).  The quality and the quantity of 
the information from behavioural testing is greatly affected by health status, energy level and testee 
co-operation (Brooks, & Knight, 2018). Distortion-Product Otoacoustic Emissions (DPOAE) testing is 
an objective, relatively time-efficient and an ear-specific way to monitor ototoxicity (Brooks, & Knight, 
2018). They can also test extended high frequencies up to 10 000 Hz (Reavis et al., 2011). Ototoxicity 
damage in DPOAE testing may be an amplitude decrease and/or a reduced signal-to-noise ratio or no 
response when measuring the outer hair cell response from the cochlea (Brooks, & Knight, 2018). 
However, there are no widely accepted norms for a significant ototoxicity change in DPOAE testing 
(Brooks, & Knight, 2018). This limits the clinical utility of DPOAE testing to be used in isolation (Brooks, 
& Knight, 2018).2.3 Disproportionate Audiologist-to-Patient Ratio 
In addition to the time consuming ototoxicity monitoring test battery (Konrad-Martin, 2014), 
there is a global lack of audiologists to conduct testing (Brennan-Jones, Eikelboom, Swanepoel, 
Friedland, & Atlas, 2016). The disproportionate audiologist-to-patient ratio results in high-patient 
caseloads and a low coverage rate for patients in need and is worse in developing countries in the 
presence of the TB epidemic increasing the patient load (Swanepoel & Biagio, 2011). For example, a 
cross-sectional population study (N = 850) done in the Limpopo province of South Africa investigated 
the prevalence of hearing loss (i.e. hearing thresholds above 25 dB HL) in the Elias Motsoaledi Local 
Municipal (Joubert & Botha, 2019). This study revealed that the prevalence rate of a hearing 
impairment was 19.88% where a disabling hearing loss was 8.94% (Joubert & Botha, 2019). Secondly, 
a cross-sectional household survey (N= 2494) was conducted in the Cape Town Metropolitan area on 
the prevalence of a hearing loss (Ramma & Sebothoma, 2016). This study revealed that 12.35% of the 
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population had a hearing impairment and that 4.57% had a disabling hearing impairment (Ramma & 
Sebothoma, 2016). As from 06 March 2020, there were only 783 audiologists registered with the 
Health Professions Council of South Africa (HPCSA) (Y. Daffue, personal communication, April 02, 
2020). A shortened test battery and test automation may be a solution for the disproportionate 
audiologist-to-patient ratio and the constantly increasing caseload.  
 
2.4 The Sensitivitve Range of Ototoxicity (SRO) Technique 
The purpose of the SRO technique is to identify an STS in hearing sensitivity in a shortened 
and customised frequency range of relatively high-frequencies (Fausti et al., 1999; Konrad-Martin et 
al., 2014). This range consists of seven consecutive frequencies that are ⅙ octaves apart (Konrad-
Martin et al., 2014; Paken et al., 2016). The SRO is a range that extends over one octave within reach 
of the patients functionally determined high-frequency hearing boundary (Fausti et al., 1999; Konrad-
Martin et al., 2014). This high-frequency hearing boundary is where the threshold is obtained at or 
below 100 dB sound pressure level (SPL) (Fausti et al., 1999; Konrad-Martin et al., 2014). The 
theoretical basis for using (relatively) high-frequencies in this technique is the notion that the basilar 
membrane of the cochlea that processes the high-frequencies are more vulnerable to ototoxic 
damage (Konrad-Martin et al., 2014). The SRO technique may be helpful as an addition to the current 
ASHA ototoxicity monitoring test battery guidelines for patients on MDR-TB treatment (Schacht et al., 
2012). 
Previous studies have shown that the SRO technique can be used to be effective and more 
time efficient as it uses a shortened frequency range to detect an STS (Fausti et al., 1999; Konrad-
Martin et al., 2014). For example, a study done by Jacobs et al. (2012) has shown that the SRO 
technique is effective in ototoxicity monitoring. Secondly, Fausti et al. (1999) used a retrospective 
analysis to show that the SRO technique is sensitive to an ototoxicity-induced hearing loss and its 
reliability in patients receiving aminoglycoside treatment. Lastly, Konrad-Martin et al. (2014) stated 
that the SRO technique significantly reduces testing time compared to conventional full-diagnostic 
hearing evaluations.  
Despite the SRO technique’s reliability and validity, it has not been adopted clinically (Konrad-
Martin et al., 2014). This may be due to lack of equipment settings to test in 1/6 octave frequencies 
when ototoxicity monitoring guidelines were established (Konrad-Martin et al., 2014). However, these 
guidelines do recommend high-frequency testing (Konrad-Martin et al., 2014). The key thing to 
consider is the value of the SRO technique in developing countries.  For example, patients will not be 
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required to concentrate for longer than necessary and it minimizes testing time allowing for more 
patients to access this service (Fausti et al., 1999; Konrad-Martin et al., 2014). On average, it takes 
approximately eight minutes to test six conventional pure tone frequencies (i.e. 250 to 8 000Hz) 
bilaterally for normal hearing patients (Swanepoel, Mngemane, et al., 2010). During ototoxicity 
monitoring, conventional (with two additional inter-octave frequencies) and extended high-frequency 
audiometry (i.e. 9000 to 16 000 Hz) need to be tested; this is approximately twelve frequencies per 
ear (ASHA, 1994) as opposed to only testing seven frequencies per ear with the SRO technique (Fausti 
et al., 1999; Konrad-Martin et al., 2014). In relation to this matter, this research aimed to explore the 
feasibility of the SRO technique in ototoxicity monitoring for patients receiving ototoxic MDR-TB 
medication within a developing country context.    
2.5 Automated Audiometry  
These studies did not use the SRO technique in conjunction with automated audiometry 
(Fausti et al., 1999; Konrad-Martin et al., 2014). Automation can contribute to the improvement of 
hearing healthcare and patient access to services as well as sustainable and cost-effective hearing 
healthcare services (Swanepoel, Clark, et al., 2010). Of importance to this research is the benefits of 
automated audiometry in ototoxicity monitoring in developing countries such as South Africa 
(Maclennan-Smith, Swanepoel, & Hall III, 2013). Automated audiometry is pure tone audiometry 
testing completed by a computer-based system and not by an audiologist (unlike manual audiometry) 
(Swanepoel & Hall III, 2010). Automated audiometry could be advantageous for assessing patients 
that have highly infectious diseases like MDR-TB (Maclennan-Smith et al., 2013; Swanepoel & Biagio, 
2011). For example, a study by O'Donnell et al. (2010) has found that South African healthcare 
professionals are more likely to get infected with MDR-TB compared to the general population due to 
occupational exposure (O'Donnell, 2010) 
In a South African context, automated audiometry will help to alleviate the high-patient 
caseloads, time constraints and limited staffing resources (Brennan-Jones et al., 2016). It may also aid 
in minimizing infection transmission as audiologists do not have to be present for testing to be 
conducted (Swanepoel & Biagio, 2011). However, automated pure tone audiometers are less useful 
in difficult-to-test patients (Swanepoel & Biagio, 2011). This is because, with manual testing, the tester 
uses his/her own discretion during testing when considering what are true responses to acoustic 
stimuli (Dille, Jacobs, Gordon, Helt, & McMillan, 2013). Previous research has validated automated 
audiometry in normal hearing and heterogenous patients (Brennan-Jones et al., 2016; Maclennan-
Smith et al., 2013). The current focus of this research was to investigate the diagnostic value and 
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sensitivity and specificity of automated audiometry in the ototoxicity monitoring of patients with 
MDR-TB using the extended high-frequency range and the SRO technique in South Africa.    
2.6 Patient-Centred Care  
The area of automation is evolving the way patients are cared for in the healthcare system 
(Cox et al., 2017). Patient experience information about a healthcare service allows for a holistic 
assessment of its quality (Auras & Geraedts, 2010). Positive patient experiences with healthcare 
services are important to ensure that quality of care is given to patients (de Silva, 2013). That is why 
healthcare has become more patient-centred (Grenness, Hickson, Laplante-Lévesque, & Davidson, 
2014). There is a lack of research with regard to patient-centred care in the field of audiology 
(Laplante-Lévesque, Hickson, & Grenness, 2014). Patient-centred care is where patients are cared for 
holistically and their inputs into their healthcare are valued (Pelzang, 2010; Ponte et al., 2003). The 
quality of the patient and healthcare professional’s interaction is a key contributor to patient-centred 
care (Grenness et al., 2014). Unfortunately, automated audiometry limits this interaction (Swanepoel 
& Biagio, 2011). Patient-centred care is directly proportional to patient satisfaction and adherence 
(Grenness et al., 2014). Patient adherence is improved if the automation (in audiometry) is perceived 
as useful and easy to use (Or et al., 2011). Automated audiometry requires the same patient 
instruction as manual audiometry (Maclennan-Smith et al., 2013). However, patient satisfaction is 
complex (Grenness et al., 2014). This research focused on patient preference as a branch of patient 
satisfaction.  
The majority of research about patient satisfaction and preference in health care are done in 
developed countries that have better infrastructure and less pressure on the health care system 
(Wang & Fung, 2014). Insufficient resources and an increase in the demand for health care services 
fuel the rise in medical disputes (Wang & Fung, 2014). Therefore, it is vital to provide feasible and 
effective health care services while not compromising on quality of care and patient satisfaction 
(Wang & Fung, 2014). Patient preference has been shown to improve patient satisfaction in health 
care (Wang & Fung, 2014).  
Patient preference has been researched in the field of audiology (Kelly, Stadler, Nelson, Runge, 
& Friedland, 2018). In a study by Kelly et al. (2018), patients were neutral on their preference between 
automated audiometry and traditional manual audiometry testing. However, in a study by Konrad-
Martin et al. (2014), patients preferred automated audiometry compared to manual audiometry 
(Konrad-Martin et al., 2014). The preference for automated audiometry may be due to the 
predictability of acoustic stimuli presentation (Swanepoel, Mngemane, et al., 2010). Unpredictable 
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acoustic stimuli presentations are more desirable to reduce false responses (Swanepoel, Mngemane, 
et al., 2010). To aid in ensuring that patient-centred care is not compromised in automated 
audiometry, the current focus of this research study was to investigate patient preference with 
automated audiometry in a South African context. 
2.7 Problem Statement  
According to Fausti et al. (1999) and Konrad-Martin et al. (2014), the SRO technique provides 
a fast and effective way of conducting hearing evaluations and detecting an ototoxicity-induced 
hearing loss in patients on ototoxic medication (Fausti et al., 1999; Konrad-Martin et al., 2014). Despite 
stated literature, there is still a lack of the clinical adoption of the SRO technique (Konrad-Martin et 
al., 2014). Furthermore, Swanepoel and Biagio (2011) and Dille et al. (2013) demonstrated the 
importance of automated audiometry in situations where audiologists are not available. Current 
hearing evaluation interval protocols practised among South African audiologists (i.e. one-month 
intervals) are also not according to ototoxicity monitoring guidelines due to high-patient caseloads 
(Govender & Paken, 2015). There is an increase in the TB epidemic (Appana et al., 2016), therefore, 
there is a need for the investigation of the feasibility of using the SRO technique with automated 
audiometry in a developing country context such as South Africa. This may promote the clinical 
adoption of the SRO technique and automated audiometry in developing countries that use ototoxic 
medication to treat MDR-TB (Adeyemo et al., 2016). 
2.8 Research Rationale   
The results of this investigation have the potential to contribute to the development of an 
appropriate ototoxicity monitoring protocol for the South Africa context. The Department of Health 
(2010) has indicated the need for context-specific evidence to create such a protocol (Management 
of drug-resistant tuberculosis: policy guidelines, 2010). Results on the incidence of an ototoxicity-
induced hearing loss (such as the time it takes for an ototoxicity-induced hearing loss to emerge once 
treatment has commenced) may provide evidence for the appropriate and practical time interval 
between follow-up testing in the ototoxicity monitoring guidelines (Fausti et al., 1999). The reliable 
use of automated audiometry in ototoxicity monitoring may aid in minimizing the high-patient 
caseloads and circumvent the challenge of an insufficient number of audiologists to conduct testing 
(Appana et al., 2016). The practicality and feasibility of using the SRO technique might contribute to a 
shortened and more appropriate test protocol (Fausti et al., 1999). This will ensure that testing is 
appropriate for ill patients (with MDR-TB) and allow more access to ototoxicity monitoring services 
(Fausti et al., 1999; Schacht et al., 2012). Patient preference between automated and manual 
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audiometry is essential for ensuring that patient-centred care is not compromised (Grenness et al., 
2014). 
Conclusion 
The impracticality of ototoxicity monitoring guidelines in South Africa need to be addressed. 
These impracticalities include appropriate testing time intervals, appropriate testing time length 
especially for ill patients and the lack of audiologists to conduct testing. The current test battery is 
comprehensive and too lengthy for fatigued patients to cope with it. However, automation and the 
SRO technique may aid in circumventing challenges currently faced with ototoxicity monitoring 
protocols in South Africa. The current clinical audiological guidelines may benefit from adopting the 
SRO technique and automated audiometry. Lastly, to ensure that new advances in technology does 
not compromise on patient-centred care, aspects such as patient satisfaction, adherence and 
preference needs to be taken into consideration.  
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  : Methodology 
This chapter will outline the aims and objectives of this research study where the feasibility of 
the automated audiometry with the SRO technique was the main aim. The various procedures used 
to achieve these aims and objectives are focused on. The research design used will be explained. The 
geographic location of the research study will be touched on. The inclusion and exclusion criteria for 
participants will be outlined in detail and rationale given for each criterion. The power of the sample 
size will be calculated, and a description of the participants recruited for the study will be described.  
The recruitment and sampling process will be explained. The instrumentation used during data 
collection and the data collection procedure (and test battery) was discussed in detail. Issues regarding 
validity and reliability, ethical considerations, and data management were addressed. Lastly, the 
process of data analysis was explained. 
3.1 Aims and Objectives    
   In patients with MDR-TB: 
1. Compare the feasibility of the SRO technique in detecting an ototoxicity-induced hearing loss with 
automated and manual (gold standard) audiometry. Objectives: 
1.1. Compare the testing time efficiency of manual and automated audiometry in conjunction 
with the SRO technique. 
1.2. Determine the parallel forms reliability of thresholds obtained using the different test 
methods (i.e. manual and automated). 
1.3. Determine the diagnostic value and the sensitivity and specificity of automated audiometry 
in conjunction with the SRO technique compared to manual testing methods (gold standard). 
2. Describe the incidence of hearing loss (determined through an STS). Objectives: 
2.1. Determine the time between ototoxic MDR-TB treatment commencement and the onset of 
a hearing loss. 
2.2. Describe the associated auditory symptoms such as tinnitus and aural fullness experienced 
by patients with MDR-TB. 
3. Describe and compare the participants’ test method preference (i.e. automated or manual 
audiometry). 
3.2 Research Design     
  A prospective repeated-measures design was used. With a prospective repeated-
measures study, participants were followed (and measured) over a period to see what ensues (Pole & 
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Bondy, 2010). Participants were chosen based on a risk factor (e.g. ototoxic medication exposure) for 
a certain pathology or possible outcome of interest (e.g. ototoxicity-induced hearing loss) (Pole & 
Bondy, 2010). The occurrence or non-occurrence (i.e. incidence) of the certain pathology or possible 
outcome of interest was then measured over time (i.e. repeated measures) (Pole & Bondy, 2010). The 
time difference between the documented risk factor’ onset and outcome of interest was an essential 
element of this research (Pole & Bondy, 2010).     
A prospective study design allowed for comparisons between the results of one or more 
diagnostic tools (e.g., automated pure tone audiometry) to a gold standard (manual pure 
tone audiometry) on the same population of interest (e.g., patients with MDR-TB) (Bossuyt et al., 
2003).  This type of design minimised recall bias and increased the accuracy of risk factor exposure 
information (i.e. ototoxic medication exposure) (Sedgwick, 2013).  
The limitations of the prospective repeated-measures study design were that it was time 
consuming, difficult to maintain contact with participants with a large sample and data collection time 
was extensive (Sedgwick, 2013). Bias may have been introduced to the study due to some participants 
being  lost  as a result of being discharged from hospital or succumbing to MDR-TB (Sedgwick, 2013).     
3.3 Research setting   
   Data collection was completed at Brooklyn Chest Hospital (BCH) and D.P Marais TB Hospital. 
These TB hospitals are situated in Cape Town, Western Cape Province. BCH is a public TB hospital with 
349 beds in several wards for the management of patients with MDR-TB (Harris et al., 2012). DP Marais 
Hospital is a specialised public district TB hospital in the Metro region’s South Peninsula Health District 
("DP Marais SANTA Hospital," 2017).   
3.4 Participants    
3.4.1 Inclusion criteria     
1) Participants that have been diagnosed with MDR-TB and have started aminoglycoside 
or bedaquiline treatment prescribed by a physician. This information was available in their 
medical records.   
a) Aminoglycosides and bedaquiline are used to treat MDR-TB (Khoza-Shangase, 2017; 
Zimmerman & Lahav, 2013). Aminoglycosides are known to have adverse ototoxic effects 
and bedaquiline has been found to be less ototoxic than aminoglycosides (Khoza-
Shangase, 2017; Zimmerman & Lahav, 2013). 
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2) Participants with MDR-TB that are in-patients and are responsive and cooperative during 
comprehensive audiological testing. Participant responsiveness and cooperativeness was 
assessed through their ability to complete comprehensive baseline testing.  
a) Majority of the countries have implemented the in-patient care model at specialised TB 
hospitals (Loveday et al., 2015).  
b) Patients in the ototoxicity monitoring program that have limited responsiveness need 
additional modifications to testing such as fewer testing frequencies or objective testing 
(ASHA, 1994).   
3) Normal hearing participants (i.e. hearing thresholds better than or equal to 25dB HL at frequencies 
250 – 8 000 Hz (WHO, 2018). This information was available in their medical records.   
a) This research aimed to look at the incidence of an ototoxicity-induced hearing loss.     
4) Participants should be able to understand and speak isiXhosa, English or Afrikaans.    
a) An exit survey was administered in isiXhosa, Afrikaans or English, depending on participant’s 
preference.    
b) Participants had to be able to understand instructions as incorrect thresholds will be obtained 
from the participant’s responses if instructions are misunderstood (Schlauch & Nelson, 
2015).   
3.4.2 Exclusion criteria 
1) Exposure to harmful occupational/recreational noise (i.e. 75 A-weighted dB; dBA) without hearing 
protection 24-72 hours prior to testing. Although it is a noncontrollable factor, participants were 
asked about exposure to noise loud enough to decrease speech perception prior to each test.    
a) The human ear can sustain damage if a stimulus intensity is above 75 dB As (Fligor, Chasin & 
Neitzel, 2015) and this noise-induced damage can confound assessment results.    
2) Participants on aminoglycoside medication in addition to other ototoxic medication such as 
Cancer treatment.   
a) The interference of other ototoxic medication act as confounding variables to the outcome of 
interest.     
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  3.5 Sample size     
Data was analysed from 54 ears of 27 participants. According to the G*Power 3.1.9.4 
calculation application (Faul, 2008), the power for this research study was 0.99. The statistical 
information that was used in this estimate is seen in Table 1.     
Table 1 
Statistical Power Information   
Parameter   Value 
Tails   Two-tailed   
Effect Size   0.50   
Type 1 error probability   0.05   
Sample size   54 (i.e. ears)   
 
3.6 Participant description 
There were twenty-seven participants in this study (23 males and 4 females). All participants 
were in-patients. The age range of the participants was from 19 to 51 years old with an average age 
of 33 years old. MDR-TB was diagnosed in twenty-five participants and two participants were 
diagnosed with pre-extensively drug resistant (XDR)-TB. Only one participant was treated with 
amikacin and kanamycin (aminoglycosides) while the rest of the twenty-six participants were treated 
with bedaquiline. Thirteen participants started their ototoxicity treatment less than a month before 
data collection started (i.e., < 31-day interval between starting treatment and starting data collection). 
Fourteen participants started their ototoxicity treatment more than a month before data collection 
started. All participants had an audiogram baseline from 250 – 16 000 Hz with normal hearing 
thresholds (i.e. 25 dB HL or better) at 250 – 8 000 Hz. Twenty-six out of the 27 participants had 
responses at all baseline frequencies (i.e. 250 – 16 000Hz). Therefore, the SRO (seven frequency range) 
was from 16 through to 8 kHz for 26 participants. One participant had an SRO from 12.5 down to 4 




 The researcher had assistance from the audiology and nursing department/staff in identifying 
patients with MDR-TB that met the requirement for normal hearing. For example, the resident 
audiologist would refer potential participants that had normal hearing (at conventional frequencies; 
250 – 8 000 Hz) during baseline testing. The researcher then identified the rest of the potential 
participants that met all criteria by looking through patient hospital records (specifically ototoxicity 
monitoring baseline assessments from 250 – 16 000 Hz). The researcher approached potential 
participants and explained the study using the informed consent form as a guide and asked potential 
participants to participate. Those potential participants that were willing to participate had to sign an 
informed consent form prior to engaging in data collection.   
3.8 Sampling 
Non-probability convenience sampling was used as it allowed for reduced costs, reduced data 
collection time and easy data collection (Etikan, Musa, & Alkassim, 2016). Convenience sampling 
depended on participant availability and willingness to participate (Durrheim & Painter, 2014) under 
the assumption of homogeneity among members of the population (Etikan et al., 2016). However, 
non-probability convenience sampling may have introduced sampling bias and as a result the sample 
may not be representative of the population (Etikan et al., 2016). The possible presence of sampling 
bias may have compromised external validity (Etikan et al., 2016).    
3.9 Data Collection     
Instrumentation:    
1) Audiological Case History: According to Beck (2015), anatomical and physiological information 
needs to be constructed and construed within the context of a patient’s case history for an 
appropriate diagnosis to be made (Beck, 2015).    
2) Standard Welch Allyn otoscope: According to ASHA’s audiometry guidelines, the pinna, ear canal 
and tympanic membrane should be visualised and inspected for foreign objects, occlusive wax, 
active infections and potential collapsing ear canals that may affect results (ASHA, 2005).     
3) Portable KUDUwave ™ audiometer: This audiometer has been developed by a South African 
company called GeoAxon Holdings (Storey, Muñoz, Nelson, Larsen, & White, 2014). This 
instrument contains sound-reduction headphones with a fully-fledged audiometer inside the 
headset compartment (Storey et al., 2014). Foam insert earphones are also used (Storey et al., 
2014). This audiometer has an automated and manual function (and the function to test remotely) 
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and covers a frequency range sensitive for the early detection of an ototoxicity-induced hearing 
loss (Reavis et al., 2011; Yu et al., 2014). The portable KUDUwave ™ audiometer allows hearing 
assessments to be conducted in suboptimal acoustic environments that are not in 
soundproof/treated booths (Swanepoel & Biagio, 2011).  This is made possible by the instrument 
continuously monitoring the level of ambient noise and attenuating sound where necessary 
(Storey et al., 2014). Here internal and external sound level meters are used to assist with ambient 
noise monitoring (Storey et al., 2014). Hearing thresholds are then only tested once ambient noise 
falls below the pre-determined noise floor (Storey et al., 2014). However, the level of attenuation 
is somewhat lower than that of a sound booth (Storey et al., 2014). 
4) Stopwatch: A smartphone stopwatch was used to determine the duration of the audiometric 
testing time for both manual and automated modes.    
5) ASHA’s STS criteria: This criteria states that a threshold shift is significant when, firstly, there is a 
20 dB decrease in hearing threshold at one frequency (ASHA, 1994). Secondly, when there is a 10 
dB decrease in hearing threshold at two consecutive frequencies (ASHA, 1994). Lastly, when there 
are no responses at three adjacent frequencies where a response was previously present (ASHA, 
1994).  The aim of the ASHA criteria was to reveal an STS in most patients, choosing to reveal false 
positives rather than delaying the detection of in a change hearing status (Waissbluth, Peleva, & 
Daniel, 2017).    
6) Short exit survey: This short exit survey was specially designed for this research by the 
researcher. The types of questions that were asked were test preference in multiple choice format 
and an open-ended question about the rationale for their test preference (see appendix A).  This 
is because patient preference is related to patient-centred care (Grenness et al., 2014). These 
questions aided in evaluating whether patient-centred care is compromised with the use of 
automated audiometry. Pertinent to this research is the fact that surveys are essential in collecting 
information on individual perspectives (Jones, Baxter, & Khanduja, 2013). Closed-ended survey 
questions are easy to analyse and present (Jones et al., 2013). Although an interview-based 
questionnaire is time consuming and requires training to avoid bias, it results in higher response 
rates and allows more complex questions to be asked (Jones et al., 2013). The researcher 
conducted this survey in the form of an interview in English, Afrikaans and/or IsiXhosa (depending 
on which language the participant preferred). The researcher had a predetermined number of 
ways to explain each question to reduce bias. Manual note taking was used during the short 




Before data collection commenced the researcher had to obtain approval from: 1) the 
University of Cape Town’s Faculty of Health Sciences’ Human Research Ethics Committee (reference 
number: 614/2018), 2) the Western Cape Government: Department of Health (reference number: 
WC_201902_004) 3) and from the clinical manager of the metro TB Hospital centre (DP Marais 
Hospital) and BCH (appendix B, C and D respectively). Participant recruitment involved the researcher 
(a master’s student) with the assistance of facility staff members.     
During recruitment, participants were assessed on whether they fit the inclusion and 
exclusion criteria. The participants’ medical records were reviewed by the researcher to see whether 
they are solely on the ototoxic drug of interest (i.e. aminoglycoside or bedaquiline medication). 
Understanding and speaking English, Afrikaans or IsiXhosa was assessed by asking the participant 
whether they understood and could speak any of the languages mentioned. The medical records were 
also reviewed to see whether the participant had normal hearing (i.e. thresholds of 25 dB HL or better 
(Schlauch & Nelson, 2015)) at baseline testing. If the participant had normal hearing, they were 
recruited and progressed to stage two of the data collection (see the data collection flow diagram in 
Figure 1).    
After recruitment, the participants were tested (follow-up testing) on a weekly basis for, at 
most, four weeks (as per ASHA’s ototoxicity monitoring guidelines if every two to three days are not 
feasible (Adeyemo et al., 2016). Participants were asked to attend weekly testing sessions for research 
purposes only as some South African audiologists do follow-up testing on a monthly (and not weekly 
basis) (Govender & Paken, 2015). As soon as a significant change in participant test results were seen 
and confirmed upon a retest, no further audiological testing was required. If no significant change in 
participant test results were seen during the last week of testing (week four), no further audiological 
testing was required for data collection. The participant, then, filled in an exit survey and exited the 
study.    
During data collection, the only new test that was added to the test procedures followed by 
most public facilities in the Western Cape are automated extended high–frequency pure tone 
audiometry and the use of the SRO technique.  The test battery used for data collection was as follows 
(see the data collection test battery in figure 2): a brief auditory symptom onset questionnaire (see 
appendix E), otoscopic examination, manual extended high-frequency audiometry using the SRO 
technique, a fifteen-minute break then automated extended high-frequency audiometry using the 
SRO technique. If a significant change in hearing sensitivity has been identified during a session, the 
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following test procedures were added to the follow-up test battery: tympanometry and conventional 
air and bone conduction manual pure tone audiometry and speech audiometry.  
The Modified Hughson and Westlake threshold searching technique was used to obtain 
hearing thresholds with both manual and automated audiometry. The Modified Hughson and 
Westlake technique is threshold searching by decreasing in 10 dB steps and increasing in 5 dB steps 
(Poling, Kunnel, & Dhar, 2016). Additionally, thresholds are only ascertained when ascending (Poling 
et al., 2016). This technique is the standard clinical procedure and was the focal point of preceding 
investigations with regards to tester bias (Poling et al., 2016). Manual audiometry started testing at 
30 dB HL for 1000 Hz only and at the previous threshold obtained for subsequent frequencies. 
Automated audiometry started testing each frequency at 30 dB HL.   
According to Appana et al. (2016), ototoxic damage occurs approximately one-month post 
treatment commencement; therefore, testing concluded after a month (four weeks) per participant 
(Appana et al., 2016). Late onset ototoxicity-induced hearing loss may also occur post treatment 
(Kolinsky et al., 2010). ASHA’s ototoxicity monitoring guidelines require follow-up testing to occur at 
least six months post treatment (ASHA, 1994). Due to time constraints, the researcher only tested a 
participant for one month maximum. When a significant decrease in hearing (as per ASHA’s 1994 STS 
criteria) or a change in ear status (i.e. an outer or middle ear pathology characterised by an abnormal 
tympanogram and/or abnormal otoscopy results) was identified, a retest was conducted within 24 
hours to confirm the result as per ASHA’s ototoxicity monitoring guidelines (ASHA, 1994). According 
to ASHA (1994), there is a high probability of a true STS if an STS relative to baseline thresholds is 
confirmed by a re-test (ASHA, 1994).     
The resident physician and audiologist were informed via medical record notes when 
participants had a decrease in hearing or change in ear status. If a middle ear pathology (i.e. change 
in ear status) has been identified and confirmed, the participant was required to exit the study. This is 
because middle ear pathologies may result in elevated extended high-frequency thresholds (Sharma, 
Munjal, & Panda, 2012). The participant was also required to exit the study upon confirmation of a 
decrease in hearing (i.e. an STS was obtained). If no decrease in hearing or ear status has been 
identified, the participant exited the study after four weeks. Upon exiting study, each participant 
completed the exit survey (using manual note-taking) and was referred to the resident audiologist for 
management and ototoxicity monitoring as per respective health facility protocol, i.e. monthly or 
every two-weeks follow-up testing (Govender & Paken, 2015). In the event of a missed 
appointment/testing session, participants were required to attend their next follow-up session. They 




    
 
Figure 1. Data Collection Test Procedure Flow Diagram 
   
   
 
Figure 2. Data Collection Test Battery 
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Participants were tested on the facility's premises in an area designated by the facility 
manager. Testing was done in the TB ward at DP Marais TB Hospital and in the audiology department 
at BCH. The researcher recorded audiological results on the recording sheet (see appendix F). The 
researcher kept the recording sheet with the participant’s name on it on the facility’s premises until 
data collection was completed for that participant. The facility manager or facility staff (e.g., 
audiological department or resident physician) was asked to assist with a secure location to keep the 
identifying patient information. After each testing session, participant results were transferred to a 
password protected OneDrive cloud under a non-identifiable numerical code for data analysis. The 
recording sheets of the participants are kept at the researcher's supervisors' office in a locked cabinet 
once data collection was completed. After five years, these documents will be shredded.    
3.11 Validity and Reliability  
One limitation of audiometry is test-retest inconsistency (Schlauch & Nelson, 2015). The 
amount of threshold variability allowed is 5 dB (Schlauch & Nelson, 2015); thus, test-retest thresholds 
needed to be within 5 dB to be considered reliable (Campbell, Hammill, Hoffer, Kil, & Le Prell, 2016). 
One frequency was retested within the same test session for each audiometric test method (i.e. 
automated and manual). Calibrated equipment was used. A tester (a master’s student) trained to use 
audiology equipment conducted testing. Researchers found that the portable KUDUwave ™ 
audiometer was reliable and valid in its manual and automated-mode of audiometric testing 
(Brennan-Jones et al., 2016). For example, the portable KUDUwave ™ audiometer has been validated 
(in normal hearing participants) outside a sound-treated room (Maclennan-Smith et al., 2013), in a 
controlled noise environment (Storey et al., 2014) and in an environment that was not sound-treated 
with a heterogeneous population (Brennan-Jones et al., 2016). Additionally, it has been demonstrated 
that extended high-frequency audiometry testing and DPOAE testing are both sensitive to  the early 
detection of an ototoxicity-induced hearing loss and complement each other well (Reavis et al., 2011; 
Yu et al., 2014). However, it should be noted that both Reavis et al. (2011) and Yu et al. (2014) used 
behavioural extended high frequency audiometry 0.5- to 20 kHz and DPOAE testing between 1 to 10 
kHz.  
 The inclusion and exclusion criteria of this research study helped reduce confounding 
variables. Participant effects on results (such as inattentiveness and fatigue) was decreased by rest 
periods between audiometry testing. Testing time was decreased by testing only seven relatively 
(depending on the highest high frequency that the participant responded to) high frequencies. The 
tester instructed participants and used procedures according to the ASHA (2005) standard audiometry 
guidelines.  External validity was compromised with non-probability convenience sampling as the 
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sample might not be representative of the population (Etikan et al., 2016). This research could only 
generalise results to members of the population that resemble the sample. The effectiveness of using 
the extended high-frequency audiometry in patients using ototoxic medication was well documented 
(Valiente, Fidalgo, Villarreal, & Berrocal, 2016). This corresponded to the theoretical basis indicating 
cochlear regions containing high-frequencies are more vulnerable to ototoxic damage (Konrad-Martin 
et al., 2014). It was, thus, the choice of test in ototoxicity monitoring (Reavis et al., 2011; Yu et al., 
2014). 
3.12 Ethical Considerations   
The ethical considerations of this research study were guided by the Declaration of Helsinki 
(WMA, 2013). The World Medical Association (WMA) states that the ethical principles of the 
declaration of Helsinki should be used as a guide in medical research that involves humans (WMA, 
2013). 
Informed consent. The standard elements of informed consent are as follows: appropriate 
information regarding the research study, participant comprehension of this information, voluntary 
participation, freedom to withdraw after data collection has commenced and a written document of 
the consent (Wassenaar, 2014). The researcher verbally informed and gave participants a written copy 
about all the information that might influence their participation in the study (see appendix G). This 
consent form was written in English, Afrikaans and IsiXhosa. The information included the study’s 
purpose, procedure, benefits and risks, refusal and termination rights, confidentiality and contact 
information. Participants had the right to withdraw from this study at any point in time without 
providing a reason. Participants had the option to receive results from the study once the study has 
been completed. 
Justice. Participants need to be treated equal and fairly during all stages of the research 
(Wassenaar, 2014). The rationale for the inclusion and exclusion criteria was evidence-based to 
maintain the principle of justice. Every potential participant that met the criteria were included in this 
study.  
Misrepresentation. According to the WMA, the researcher is accountable to the accurateness 
and completeness of the reports on human participants (WMA, 2013). Results obtained during data 
collection were not fabricated. Information used from the works of others are cited according to the 
American Psychological Association’s (APA) sixth edition.   
Loss of privacy and confidentiality. This study required some form of participant identification 
(such as patient name) as participants were tested on multiple occasions. The protection of participant 
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confidentiality is fundamental to respect for persons (Wassenaar, 2014). Once data collection was 
complete, each participant was assigned a numerical code and their personal details erased. 
Participant information (numerical code used and not participant name) and results were entered 
onto a password protected cloud such as Microsoft OneDrive as data is collected. This ensured that 
confidentiality was still maintained during adverse events such as theft. Any hard copies of the 
participant information are kept in a locked cabinet in the researcher’s supervisor’s office. This 
information will be shredded after for five years.  
Beneficence. Caution needs to be taken when evaluating the potential risks and benefits to 
human participants in medical research (Wassenaar, 2014). In accordance with the Declaration of 
Helsinki (WMA, 2013), the risks were continuously monitored throughout the study.  
Risks and benefits.  
• Participants may have been overexerted while being tested with audiometry twice within an 
hour on a weekly basis. The time interval between tests was a maximum of fifteen minutes 
allowing participants enough time to rest in between tests. Each audiometric test was reduced 
from twelve frequencies (as per ASHA’s protocol) to testing only seven frequencies per ear.  
• Participants may have experienced distress when hearing that they have developed a hearing 
loss. Counselling and a referral to the resident audiologist and physician for management (part of 
routine hospital care) was provided in such instances.   
• The researcher had the risk of contracting MDR-TB. Precautions such as wearing an 
appropriate TB mask, wearing gloves when evaluating participants and making sure that the 
windows of the test room were always open was taken. 
• Direct participant benefit:  
o Participants were compensated with R50 for each session attended to cover 
associative costs (such as travelling fare to and from the hospital if the participant was 
discharged from hospital) related to participating in the study.    
o Participant satisfaction of being involved in a scientific study (Cozby, 2009).  
• General/professional benefit:  
o Contribution to practical ototoxicity monitoring guidelines in developing countries 
such as South Africa.  
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o Evidence for a feasible ototoxicity monitoring protocol such as automation with the 
SRO technique.  
o Test time reduction (to seven frequencies) making test battery more appropriate for 
weak patients such as those with MDR-TB.  
o Reduction of high caseloads allowing more access to health care through automation.  
3.13 Data Management 
The data collected for this research study was recorded on a hard copy during the testing 
session. The raw data recorded included: 1) a participant identification code (i.e. 1,2, etc.), age and 
gender, 2) the name of the MDR-TB treatment previously and/or currently being received and the 
date that it started (e.g., amikacin, kanamycin, bedaquiline, etc.), 3) the auditory symptoms 
participants reported (ear specific where possible), 4) otoscopic results, 5) tympanometry results, 5) 
the date and time frame for each audiometric test, 6) the hearing thresholds for both manual and 
automated audiometry, 7) the state of the participants (e.g., fatigued) for each session, and 8) the exit 
survey multiple choice option and rationale given by the participant. The participant's name and 
respective identification code were recorded on a separate sheet. 
After each session, the data was stored as a portable document file (PDF) and uploaded onto 
a password-protected cloud, Microsoft OneDrive. The data was also recorded on an excel 
spreadsheet, on Microsoft OneDrive. Each objective had a different excel spreadsheet. Each 
spreadsheet had an introductory page that outlined the objective and described the type of variable 
and data needed to answer the objective. Each spreadsheet was formatted in a way that made reading 
and analysing the data convenient. 
Data entry was done on the same day as data collection. Each facility requested that test 
results be recorded in the participants' medical files. Data entered was rechecked for errors at the end 
of each week. Data entry checks were also done at the end of data collection for each participant on 
two separate occasions. The PDF and hard copies of the data were given to the research supervisor to 
store on her password-protected computer and locked cabinet in her office. The data will be shredded 
after five years. 
 3.14 Data Analysis  
The research study’s data was analysed using descriptive and inferential statistical methods. 
The sample demographics was expressed using descriptive statistical methods such as frequency 
distribution tables. Descriptive statistics is used to describe the data or describe the relationship 
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among the data (Durrheim, 2014). Inferential statistics is used to make judgements and conclusions 
based on the data acquired from a sample (Durrheim, 2014). A Bonferroni corrected p-value was used 
because numerous independent or dependent inferential statistical tests were being made 
simultaneously using one sample (Napierala, 2012). This was the case for this research study. The 
formula for the Bonferroni corrected p-value is p-value (for this study it was 0.05) divided by the 
amount of comparisons made (Napierala, 2012). Table 2 shows how results were analysed.  
Table 2 
Data Analysis Table 
Aim/Objective Type of data Variable Descriptive Statistics Inferential Statistics 




audiometry using the 
SRO technique 
Ratio Test duration 
(in minutes) 
• Mean 
• Standard deviation 
• Subtraction (i.e. 
mean difference) 
• Paired samples 
t-tests 
1.2 Test-retest 







• None • Pearson’s 
correlation 
coefficient 
• Paired sample’s 
t-test  
 
1.3 Diagnostic value 
and the sensitivity, 
and specificity of 
automated 
audiometry with the 
SRO technique 
compared to manual 
audiometry 
Binary Absence of 
presence of 
an STS 









2.1 Time interval of 
the onset of an STS 
after starting MDR-TB 
treatment 


















3. Patient with MDR-












Objective 1.1: the variable of interest was time (in minutes) and this was expressed as ratio 
data. The average (mean) test duration (in minutes) of manual and automated audiometry was 
measured. The standard deviation for each test method was calculated to see how widely spread 
individual test durations are from the mean (i.e. central tendency) of each test method (Durrheim, 
2014). The mean values of each test method were subtracted from one another to indicate which 
test method was more time efficient (i.e. shorter test duration). Paired samples t-tests were used to 
see whether the difference in testing time between the test methods were significant. A paired 
sample’s t-test is used to compare the means of two samples where sample data was obtained from 
the same sample group (Nunez, 2013). 
Objective 1.2: the variable of interest was hearing thresholds in dB HL and this was expressed 
as interval data.  The paired sample’s t-test was used to compare the thresholds obtained between 
manual and automated audiometry. This analysis was frequency (i.e. 4 – 16 kHz) and ear specific. The 
Pearson’s Correlation Coefficient test (r) was used to calculate the strength of the relationship 
between thresholds obtained through manual and automated audiometry for each frequency tested 
(Lachenicht, 2013).  
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Objective 1.3: the variable of interest was the presence or absence of an STS and this was 
expressed as binary data. Receiver Operating Characteristic Curves are essential in evaluating a 
diagnostic tools ability to accurately detect a true result (i.e. the area under the ROC curve) (Altman 
& Bland, 1994; Hajian-Tilaki, 2013). ROC characteristics measure the diagnostic value of a test 
compared to a gold standard (Kumar & Indrayan, 2011). According to Hajian-Tilaki (2013), if the area 
under the curve is 1 it is near perfect detecting the presence or absence of a disease (Hajian-Tilaki, 
2013). However, if the area under the curve is 0.5 or below that means that there was a chance 
discrimination during classification of the presence or absence of a disease (Hajian-Tilaki, 2013). Lastly, 
if the area under the curve is 0, the test incorrectly classifies the presence or absence of a disease 
(Hajian-Tilaki, 2013).  Here, the presence or absence of an STS was coded as ‘1’ and ‘0’ respectively. 
This was done for both manual and automated audiometry. A 2x2 table was also used to evaluate the 
sensitivity and specificity of a test (i.e. automated audiometry with the SRO technique compared to 
manual audiometry) (Shaikh, 2011). The formula for sensitivity was as follows: number of true positive 
(TP) results divided by the number of TP results added to the number of false negative (FN) results 
(i.e. TP/(TP+FN)) (Shaikh, 2011). The formula for specificity was as follows: number of true negative 
(TN) results divided by the number of TN results added to the number of false positive (FP) results (i.e. 
TN/(TN+FP)) (Shaikh, 2011). 
Objective 2.1: the variable of interest was time (in days), and this was expressed as ratio 
data. A frequency distribution table and percentiles were used to show the frequency with which a 
certain time (in days) difference of ototoxicity-induced hearing loss onset occurred. A box and whisker 
plot showing the time difference obtained was measured. This gave the researcher an indication of 
the data set’s central tendency (Tredoux & Durrheim, 2013). There were no inferential statistical 
measurements for this objective.  
Objective 2.2: the variable of interest was auditory symptoms, and this was expressed as 
categorical data. A frequency distribution bar graph and percentiles were used to show the frequency 
with which a certain auditory symptom was reported among participants with MDR-TB. There were 
no inferential statistical measurements for this objective.  
Aim 3: the variable of interest was test preference, and this was expressed as categorical data. 
A frequency distribution table and percentiles were used to show the frequency of multiple options 
that correspond to the preference of manual, automated, none or both test methods. The rationale 
given by participants were also expressed in the table. There were no inferential statistical 




 Results  
This chapter will report on the results obtained for each objective. The testing time efficiency, 
hearing threshold parallel forms reliability, diagnostic test value and the specificity and sensitivity of 
automated audiometry and manual audiometry analysis will be shown under the first aim. The 
incidence of an STS (i.e. the time it takes for an STS to occur) and the associated auditory symptoms 
of ototoxicity will be described under the second aim. Lastly, the test method preference will be 
described under the last aim. 
4.1 Aim 1: Compare the feasibility of the SRO technique in detecting an ototoxicity-induced 
hearing loss with automated and manual (gold standard) audiometry. 
• Testing time efficiency between manual and automated audiometry. 
On average, manual audiometry had a faster testing time (M= six minutes and five seconds) 
compared to automated audiometry (M= seven minutes 14 seconds) by one minute and ten seconds. 
Manual audiometry was more varied in testing time (SD= two minutes and 25 seconds) compared to 
automated audiometry (SD= one minute and 36 seconds). The difference between manual audiometry 
testing time and automated audiometry testing time obtained revealed a statistically significant 
difference using a paired samples t-test where t (94) = -5.44; p < 0.003.   
• Reliability of thresholds obtained using the different test methods 
At all frequencies, there was a strong positive correlation for both left and right ears between 
the thresholds obtained from manual and automated audiometry (r(28) > 0.70, p < 0.003 excluding 4 
and 6 kHz) (see table 3). This correlation is statistically significant (p < 0.003; alpha level based on 
Bonferroni correction) at 8, 9, 10, 11.2, 12.5, 14 and 16 kHz. However, the correlation is not statistically 
significant at 4 and 6 kHz for both left and right ears (p > 0.003). This is because the results of one 
participant was used to analyse parallel forms of reliability at 4 and 6 kHz as only one participant had 
an SRO that included these two frequencies. The results obtained for 4 and 6 kHz are excluded from 
the discussion of the results due to limited number of pairs contributing to the analysis of the data. 
Results were excluded from analyses when no response was obtained during testing.  
Table 3 
Correlations Between Thresholds Obtained from Manual and Automated Audiometry  
Frequency  N*  r  p (two-tailed)  
4 kHz Right Ear  4  0.88  0.12  
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4 kHz Left Ear  4  0.92  0.08  
6 kHz Right Ear  3  0.88  0.32  
6 kHz Left Ear  2  0.91  0.28  
8 kHz Right Ear  95  0.92  0.000  
8 kHz Left Ear  95  0.86  0.000  
9 kHz Right Ear  95  0.89  0.000  
9 kHz Left Ear  95  0.91  0.000  
10 kHz Right Ear  92  0.92  0.000  
10 kHz Left Ear  92  0.93  0.000  
11.2 kHz Right Ear  91  0.90  0.000  
11.2 kHz Left Ear  91  0.95  0.000  
12.5 kHz Right Ear  87  0.95  0.000  
12.5 kHz Left Ear  87  0.96  0.000  
14 kHz Right Ear  74  0.94  0.000  
14 kHz Left Ear  74  0.94  0.000  
16 kHz Right Ear  30  0.98  0.000  
16 kHz Left Ear  30  0.94  0.000  
Note. Bonferroni corrected p-value = 0.05/18 = 0.003.  
*N was derived from the number of times a frequency was tested among all participants.  
The difference between thresholds obtained from manual audiometry and automated 
audiometry are not statistically significant for the left and right ear results at all frequencies tested 
(paired samples t-test; p> 0.003). (see table 4). On average, poorer thresholds were obtained with 




Differences Between Thresholds Obtained from Manual and Automated Audiometry  
Frequency  M  SD  Standard Error  95% CIs  t  df  p (2-tailed)  
4 kHz Right Ear  -6.25  9.46  4.73  -21.31, 8.81  -1.32  3  0.278  
4 kHz Left Ear  -6.25  12.5  6.25  -26.14, 13.64  -1.00  3  0.391  
6 kHz Right Ear  -10  17.32  10  -53.03, 33.03  -1.00  2  0.423  
6 kHz Left Ear  -6.67  11.55  6.67  -35.35, 22.02  -1.00  2  0.423  
8 kHz Right Ear  -0.89  5.74  0.59  -2.03, 0.27  -1.52  94  0.132  
8 kHz Left Ear  -0.79  8.51  0.87  -2.52, 0.95  -0.90  94  0.368  
9 kHz Right Ear  -1.42  7.84  0.80  -3.02, 0.18  -1.77  94  0.081  
9 kHz Left Ear  -0.84  7.60  0.78  -2.39, 0.71  -1.08  94  0.283  
10 kHz Right Ear  -0.27  7.00  0.73  -1.72, 1.18  -0.37  91  0.711  
10 kHz Left Ear  -0.49  6.50  0.68  -1.84, 0.86  -0.72  91  0.473  
11.2 kHz Right Ear  -0.88  8.01  0.84  -2.55, 0.79  -1.05  90  0.298  
11.2 kHz Left Ear  0.16  6.64  0.70  -2.22, 1.55  0.24  90  0.813  
12.5 kHz Right Ear  -0.63  5.75  0.62  -1.86, 0.59  -1.03  86  0.308  
12.5 kHz Left Ear  -0.63  5.64  0.61  -1.84, 0.57  -1.05  86  0.299  
14 kHz Right Ear  -0.41  6.34  0.74  -1.88, 1.06  -0.55  73  0.584  
14 kHz Left Ear  1.42  7.61  0.88  -0.34, 3.18  1.60  73  0.113  
16 kHz Right Ear  0.83  3.73  0.68  -0.56, 2.23  1.22  29  0.231  
16 kHz Left Ear  -0.50  6.48  1.18  -2.92, 1.92  -0.42  29  0.676  
 
• The diagnostic value and the sensitivity and specificity comparisons of automated 
audiometry to manual testing  
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The ROC curve revealed that automated audiometry is a fair diagnostic test (area > 0.7). This 
can be seen by the area under the curve being 0.75 (SE = 0.07, 95% CI (0.62, 0.89), p = 0.002).  
 Moreover, both automated and manual audiometry agree 61% of the time when a significant 
change in hearing sensitivity has occurred (i.e. sensitivity) and agree 90% of the time when no 
significant change in hearing sensitivity has occurred (i.e. specificity) (see figure 3).  
  
Blue line: ROC curve; Red line: Reference line indicating no sensitivity and no specificity 
Figure 3. Sensitivity and specificity of automated audiometry with the SRO technique in detecting an 
STS 
Table 5 describes the frequencies at which automated and manual audiometry give the same 
and different diagnostic results. The sensitivity (i.e. (TP/(TP+FN))*100) was 61% and specificity (i.e. 
(TN/(TN+FP))*100) was 90%.  
Table 5 
Correspondence between automated and manual audiometry to determine an STS  
 Manual – STS Manual – no STS 
Automated – STS 14True Positive (TP) 3False Positive (FP) 




4.2 Aim 2: Describe the incidence of hearing loss (determined through an STS).  
• The time between MDR-TB treatment commencement and the onset of a hearing loss. 
Only participants that started MDR-TB treatment at most 31 days before data collection 
commenced were included in the analysis of this objective (n=13 out of 14 participants). Baseline 
assessments were either done within week one (three participants; 23%), week two (four participants; 
30%), week three (23% of participants) or within the fourth week (23% of participants) after starting 
MDR-TB treatment. Of these thirteen participants, only eight participants had an STS during data 
collection. However not all participants had a bilateral STS, therefore, each ear with an STS (i.e., 10 
ears) was analysed separately (see table 6). 
Table 6 
Frequency Distribution of the Time Interval of the Onset an STS 
Variable (Time in Days)  Number of Ears  Percentage of 
Participants with an STS (%)  
1-9  0  0%  
10-19  2  20%  
20-29  2  20%  
30-39  2  20%  
40-49  3  30%  
50 and above  1  10%  
Note. Ears without an STS were excluded from the analysis (n=16 ears). 
 
The time interval between the onset of an STS and the start of MDR-TB treatment data was 
skewed to the right as the data varied more between the median and the maximum value than the 
minimum and the median (see figure 4). An STS indicating an ototoxicity-induced hearing loss was 




Figure 4. STS onset time interval (in days) graph 
• Associated auditory symptoms reported 
Figure 5 displays the frequency of auditory symptoms among participants before hearing tests 
were conducted. Fifty-six percent of participants (n=15 out of 27) reported auditory symptoms, with 
aural fullness the most frequently mentioned (53.33%; n=8 out of 15 participants). Case history 
information revealed that 44.44% (n=12 out of 27) participants had a history of occupational noise 
exposure (i.e. more than 72 hours prior to data collection). Most of the participants (53.33%; n= eight 
out of 15) that reported auditory symptoms started their treatment more than a month before data 
collection. Secondly, majority of the participants (67%; n= 10 out of 15) that reported auditory 
symptoms had an STS. In addition, all participants that reported aural fullness (n=8) had an STS. No 
new symptoms were reported throughout the data collection.  
 
Figure 5. Frequency of other Reported Symptoms 
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4.3 Aim 3: Ototoxicity Monitoring Test Method Preference (Manual Versus Automated 
Audiometry)  
The exit survey was completed by 19 (70.37%) participants. Eight participants (29.63%) did 
not complete the exit survey because they were discharged before data collection was completed (see 
table 7). Most participants had no preference between the two testing methods.  
Table 7 
Patient Test Method Preference  
Preference  n Rationale  
No Preference  13  “No difference noted”  
Manual Audiometry  3  “easier,” “quicker,” or “had a clearer sound”  





 Discussion  
This chapter interprets the results obtained and analysed in chapter four. Each objective is 
delved into separately. The first three objectives attempt to answer the main aim of the feasibility of 
the SRO and automated audiometry. The objectives for the secondary aim (i.e. incidence of an STS) 
and tertiary aim (i.e. test method preference) are discussed subsequently. How results obtained relate 
to previous studies are described and the implications for future research and clinical guidelines are 
also discussed. This chapter also discusses the limitations faced by the research study, the conclusion 
and recommendations for future research.  
5.1 SRO testing time efficiency between manual and automated audiometry   
Results from this research study showed that manual audiometry was more time efficient 
compared to automated audiometry. The results of this study did not correlate with Swanepoel, 
Mngemane et al., (2010), where manual and automated audiometry testing time was found to be 
similar (7.2 to 7.7 minutes on average) (Swanepoel, Mngemane, et al., 2010). However, Swanepoel, 
Mngemane et al., (2010), used normal hearing participants. Swanepoel, Mngemane et al., (2010) 
varied the order in which testing occurred (e.g., Manual than automated audiometry or automated 
audiometry than manual audiometry). This study did not counterbalance the test order. Secondly, 
MDR-TB treatment is known to cause fatigue resulting in patients being difficult to test (Swanepoel & 
Biagio, 2011). MDR-TB treatment has numerous side effects that negatively affect audiometry testing 
as it requires concentration for long periods of time (Paken et al., 2016; Schacht et al., 2012). Manual 
audiometry was always tested prior to automated audiometry during data collection. This may have 
contributed to manual audiometry being more time efficient compared to automated audiometry. 
This could also have influenced thresholds obtained through automated to be poorer (on average) 
compared to manual audiometry. Thirdly, although both automated and manual audiometry used 
the Modified Hughson and Westlake threshold searching technique, manual audiometry started 
testing at 30 dB HL at 1 000 Hz only while automated audiometry started testing each frequency at 30 
dB HL and perhaps why automated audiometry was found to be less time efficient.  Based on this 
finding, future research can look at programming automated audiometry with the same threshold 
search manner in which manual audiometry is conducted (i.e. starting at 30 dB HL at 1000 Hz only and 
not at all frequencies) in an attempt for it to be more time efficient. Lastly, the average time difference 
between manual and automated audiometry using the SRO technique may be statistically significant 
but both test methods’ testing average is more practical than the current test battery for difficult to 
test patients that have limited concentration.  
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Furthermore, the SRO technique is more time efficient (with either manual or automated 
testing) compared to traditional ototoxicity monitoring methods (Fausti et al., 1999). Traditional 
ototoxicity monitoring tests conventional frequencies (0.25 to 8 kHz; taking approximately eight 
minutes) plus additional testing such as extended high-frequency testing (9 to 16 kHz) (Swanepoel, 
Mngemane, et al., 2010). The SRO technique only tests seven frequencies per ear that are separated 
by 1/6 octaves (Dille et al., 2013). Thus, the SRO technique is beneficial for patients that are too ill to 
concentrate for extended periods of time (such as that required for traditional ototoxicity 
monitoring) (Dille et al., 2013).   
5.2 Parallel forms reliability between automated and manual audiometry  
Thresholds obtained with both manual and automated audiometry were positively correlated 
in this study. Similar thresholds were obtained from both testing methods. This result correlated with 
the study done by Swanepoel and Biagio, (2011) and Swanepoel, Mngemane, et al., (2010) that 
found that the air conduction thresholds obtained with the automated audiometry 
(using the KUDUwave ™) correlated 90% of the time with standard manual audiometry (Swanepoel & 
Biagio, 2011; Swanepoel, Mngemane, et al., 2010). Yeung et al. (2013) obtained highly reliable results 
when using automated audiometry in a sound treated room compared to the conventional testing 
(Yeung et al., 2013). Similarly, Brennan-Jones et al. (2016) and Maclennan-Smith et al. (2013) validated 
automated audiometry in normal and heterogenous populations (Brennan-Jones et al., 2016; 
Maclennan-Smith et al., 2013). Some studies such as Lemkens et al. (2002) deemed a 10 
dB HL difference between automated and manual audiometry thresholds as agreeable (Thompson, 
Sladen, Borst, & Still, 2015). However, this research study considered a maximum of 5 dB HL difference 
as reliable. Furthermore, all studies reported no statistically significant differences between 
automated and manual audiometry testing (Mahomed, Swanepoel, Eikelboom, & Soer, 2013).   
Automation has the potential to improve the standardisation of testing protocols across 
health care facilities (Mahomed et al., 2013). A systematic review and meta-analysis done by 
Mahomed et al. (2013) has found that automated audiometry has the same amount of test-retest 
variability as manual audiometry does (Mahomed et al., 2013). Automated audiometry cannot 
supersede the need for an audiologist but a computerised system that can obtain pure tone 
thresholds just as accurately is beneficial for the disproportionate patient and audiologist ratio 
(Mahomed et al., 2013).  Thus, automated audiometry can form part of the clinical guidelines as it 
allows for standardisation across testing.  
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5.3 The sensitivity and specificity of using automated audiometry   
The assessment of a diagnostic test is vital in the modern field of health sciences for detecting 
the presence or absence of a disease (Hajian-Tilaki, 2013). This allows for the high-quality of diagnostic 
information in a field like audiology (Beck, 2015). This research study found that automated 
audiometry is a fair diagnostic test (area under ROC is 0.75). This finding correlated with Mahomed et 
al. (2013) stating that automated audiometry is largely valid (Mahomed et al., 2013). This research 
study showed that automated audiometry accurately identified the absence of an STS 90% of the time. 
However, this research study revealed that the presence of an STS was only accurately identified 
60.1% of the time. Similar studies comparing automated audiometry with manual audiometry have 
found a 90% specificity and 88.9% sensitivity in a non-sound treated room with heterogenous 
participants (Thompson et al., 2015). Yeung et al (2013) found a 93.3% specificity and 94.5% sensitivity 
in a sound treated room with normal hearing participants (Yeung et al., 2013). In these studies, the 
reliability of thresholds had to be within 10 dB HL (Lemkens et al., 2002 as cited by Thompson et al., 
2015). However, for this research study, a difference within 5 dB HL (which is a more stringent 
criterion) was needed for a threshold to be considered reliable. Secondly, the presence or absence of 
an STS (i.e. binary data) was used when calculating the ROC characteristic not hearing thresholds. 
Thirdly, the ASHA criteria were used to determine the absence or the presence of an STS (Waissbluth 
et al., 2017). The ASHA criteria were developed to determine most cases of ototoxicity and focuses 
more on the detection of false positives (i.e. reducing the number of referrals for confirming an 
STS) (Waissbluth et al., 2017). Fourthly, pure tone audiometry testing is largely affected by 
the testee’s willingness (and ability) to cooperate and respond when a sound is heard (Schlauch & 
Nelson, 2015). MDR-TB treatment has adverse side effects that strain the body, causes fatigue and a 
lack of concentration during testing (Paken et al., 2016; Schacht et al., 2012). This leads to difficulty 
coping with (subjective) audiometry testing (Walker, Cleveland, Davis, & Seales, 2013). For example, 
if a patient does not respond within a certain time period, the system records it as a ‘'no response’' 
and subsequently increases the intensity (Swanepoel, Mngemane, et al., 2010). An audiologist can 
detect an inaccurate response when no change in hearing is suspected and resolve this while 
automated audiometry is at a disadvantage as it is algorithm based (Dille et al., 2013). Therefore, when 
a patient is difficult to test, manual audiometry is best (Dille et al., 2013). However, automated 
audiometry has better test-retest reliability compared to manual audiometry as threshold-seeking is 
done frequently without bias (Jerlvall, 1983 as cited by Swanepoel, Mngemane, et al., 
2010). Additionally, high-frequency DPOAE testing, an objective test, can be used as an adjunct to 
automated audiometry (Reavis et al., 2011). Reavis et al. (2011) found that DPOAEs are strong 
predictors for ototoxicity induced hearing threshold shifts.  
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5.4 Incidence of an ototoxic-induced hearing loss in participants with MDR-TB   
This research study revealed that most of the participants (38.46% of ears; n=10 out of 16) 
experienced an STS in hearing after an average of 33 days (median of 33 days; data was skewed to the 
right) after starting MDR-TB treatment. However, a true baseline could not be obtained (i.e. 
participants could not be tested prior to starting MDR-TB medication). This finding correlates to a 
longitudinal study done by Appana et al. (2016) stating that an ototoxicity-induced hearing loss 
appears after one month of starting ototoxic MDR-TB treatment (Appana et al., 2016). However, there 
is also conflicting literature available that states that an ototoxicity-induced hearing loss can occur 
immediately after starting MDR-TB treatment, three to four days after starting MDR-TB treatment, or 
after the completion of MDR-TB treatment (De Jager & Van Altena, 2002; Kolinsky et al., 2010; Sara et 
al., 2014).  The variability regarding the incidence of an ototoxic-induced hearing loss is affected by 
assessment protocol parameters, participant characteristics and the normative/standard criteria used 
to determine an STS (Xie, Talaska, & Schacht, 2011). Additionally, the incidence of ototoxicity depends 
on the duration and dosage of ototoxicity treatment (Xie et al., 2011).  
5.5 Other auditory symptoms reported by participants on MDR-TB   
Aural fullness was the most reported symptom. All the participants that reported aural 
fullness (n=8) at the start of data collection obtained an STS (i.e. ototoxic damage) during data 
collection. This result correlates with Cianfrone et al. (2011)’s findings that state that tinnitus, 
dizziness, hyperacusis, aural fullness and hearing loss are symptoms associated with ototoxicity. These 
symptoms vary among individuals and ototoxic drugs (Bisht & Bist, 2011). However, a study done 
by Javadi et al. (2011) found that individuals typically do not experience any audiological symptoms 
prior to the onset of an ototoxic-induced hearing loss (Javadi et al., 2011). Moreover, Bisht 
and Bist (2011) reported that extended high frequency audiometry can detect an ototoxic-induced 
significant shift in hearing prior to experiencing tinnitus or a perceived hearing loss (Bisht & Bist, 
2011). In addition to aural fullness, a history of noise exposure was also reported among participants. 
This research study found that 44.44% of participants reported a history of noise exposure. Of the 10 
ears that were used in the analysis of the incidence of an STS, 38.46% had an STS. Excessive noise can 
damage the hair cells of the cochlea and cause a permanent hearing loss (Filgor et al., 2015). This is as 
a result of the metabolic change that occurs in the cochlea (Filgor et al., 2015). A gradual onset of a 
cochlea hearing loss may also be due to a history of excessive noise exposure that may range from 75 
to 78 dBA to 132 dBA (Melnick, 1991 and as cited by Filgor et al., 2015). It should be noted that most 
participants that had reported auditory symptoms (53.33%; n= eight out of 15) participated in this 
study’s data collection more than a month after starting their MDR-TB treatment. This time delay 
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between starting MDR-TB treatment and data collection may have contributed to the results. 
Therefore, future research may need to look at the accurate incidence of auditory symptoms 
compared to an STS in individuals receiving ototoxic medication with weekly ototoxicity monitoring 
using the SRO technique. Lastly, aural fullness may indicate a pathology in any part of the peripheral 
hearing pathway (Park et al., 2012). It is said to be omnipresent (Park et al., 2012). Therefore, patients 
reporting aural fullness as the primary complaint need to undergo a diagnostic hearing evaluation. 
Various pathologies may have aural fullness as a symptom (Park et al., 2012).  
5.6 Ototoxicity Monitoring Test Method Preference    
Most of the participants (n=13) that completed the exit survey had no preference between 
manual or automated audiometry testing. The common reason was that “no difference was noted.’' 
This finding correlates with a study done by Kelly et al. (2018), that found that participants had a 
neutral response between automated and manual audiometry (Kelly et al., 2018). The reason for this 
could be that automated and manual audiometry have the same instructions and test procedures 
(Maclennan-Smith et al., 2013). This finding shows automation will be useful in improving the 
disproportionate audiologist and patient ratio by decreasing the caseload (Swanepoel & Biagio, 2011) 
without negatively affecting patient satisfaction or possibly compromising on patient-centred care as 
participants prefer either testing methods (Wang & Fung, 2014). Secondly, the participants that did 
have a preference were equally distributed (i.e. n=3 each) among automated or manual audiometry. 
A ‘'clearer sound” was the reason preferring both automated or manual audiometry.  This does not 
correlate with a similar study done by Konrad-Martin et al. (2014) that found that participants 
preferred automated audiometry and Swanepoel, Mngemane et al. (2010) suggested that it is due to 
automated audiometry’s predictable nature when presenting stimuli (Konrad-Martin et al., 2014; 
Swanepoel, Mngemane, et al., 2010). It should be noted that manual audiometry may have been 
preferred by some participants as it requires the tester to decide on whether there was a response or 
not (Schlauch & Nelson, 2015). This finding is especially useful when testing difficult-to-test patients 
(Swanepoel & Biagio, 2011). As previously mentioned, MDR-TB medication has adverse side effects 
on individuals with MDR-TB resulting in them having decreased concentration levels (Paken et al., 
2016). Also, there is limited research on how patients (and clinicians) experience the advances in 
technology innovation (especially in the field of audiology) where technology innovation is 
continuously evolving (Ng, Phelan, Leonard, & Galster, 2017). More in-depth research studies will be 
beneficial to understand and create more ways to improve on patient satisfaction (Ng et al., 2017).  
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5.7 Limitations   
This research study could not recruit participants that were newly diagnosed with MDR-TB 
due to a lack of referrals to the health facilities where data was being collected. The participants were 
still recruited if they had normal hearing. Initially, this study aimed to test patients 
on amninoglycosides (known to cause ototoxicity), however, most participants with MDR-TB were 
enrolled in the new MDR-TB treatment regimen where Bedaquiline was used ("Bedaquiline roll-out," 
2018; Zimmerman & Lahav, 2013). Therefore, participants on BDQ had to be recruited as well. Most 
participants had already started MDR-TB treatment more than a week before data collection 
commenced. This resulted in some participants being excluded when analysing the incidence of 
an ototoxicity-induced hearing loss. Baseline testing was not done as part of the research study. This 
degrades the reliability when assessing the incidence of an ototoxicity-induced hearing loss analysis. 
All participants were in-patients. Contact was lost with the patient as soon as they were discharged 
from hospital resulting in incomplete data and limited number of participants completing the exit 
survey. However, the data already collected for these participants were still used during data 
analysis.  Lastly, this research study could have benefited from a pilot study. A pilot study where the 
test-retest reliability of each test method could have been assessed prior to the prospective repeated-
measures design used for this research. A pilot study would have enhanced the reliability of the 
current research study. 
5.8 Conclusion and Recommendations   
This study found that manual audiometry was more time efficient compared to automated 
audiometry. It was discussed that the test method settings in automated audiometry need to be 
adapted more similarly to how manual tests are currently conducted to obtain similar testing time 
efficiency results. Ototoxicity monitoring programs could also consider using the SRO technique in 
patients that are easily fatigued because of MDR-TB medication. The SRO technique has been shown 
in previous studies (Dille et al., 2013; Swanepoel, Mngemane, et al., 2010) to be more time efficient 
compared to traditional ototoxicity monitoring methods. Equipment settings can be changed to 
accommodate testing frequencies in 1/6 octaves so that the SRO technique can be clinically adopted 
(Konrad-Martin et al., 2014). Automated audiometry is a fair diagnostic test in patients with MDR-TB. 
However, using automated audiometry in difficult to test patients gives a less accurate sensitivity. 
Clinically, automated audiometry with the SRO technique is time efficient, objective and it allows 
for standardisation (Swanepoel, Mngemane, et al., 2010). A true baseline could not be obtained to 
report accurately on the incidence of an STS. Therefore, the accurate incidence of an STS still needs to 
be investigated (Bisht & Bist, 2011). Aural fullness was observed to be the most reported symptom 
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among participants. Aural fullness is one of the symptoms associated with ototoxicity as found in 
previous studies (e.g., Cianfrone et al., 2011). Aural fullness may be present in both middle ear and/or 
inner ear pathologie (Park et al., 2012). Therefore, this symptom needs to be investigated fully and 
may not be a simple/elementary symptom (Park et al., 2012). No test method preference was 
reported by participants. It seems that the introduction of automated audiometry has not impacted 
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6.1 Appendix A: Short Exit Survey 
Exit Survey On Patient Test Method Preference 
 
1) Which test would you like to do in the future?  
a) Automated Test (where the researcher was not present) 
b) Manual Test (where the researcher was doing the testing) 
c) Any of the two tests  























6.4 Appendix D: Clinical Manager of the Metro TB Hospital centre (DP Marais Hospital) and 





6.5 Appendix E: Auditory Symptom Questionnaire 
Auditory Symptom Questionnaire 
1. Have you had any exposure to loud noise/music (For example, you had to raise your voice 
to hear yourself speak)?  
Yes/No:    
2. Are you experiencing any tinnitus sensations (for example, you hear sounds in your ear 
without the sound coming from the environment)?  
Yes/No:  
Is yes, is it in both ears, the right ear or the left ear?    
3. Does your ear feel blocked?  
Yes/No:  
Is yes, is it in both ears, the right ear or the left ear?    
4. Do you feel dizzy or off balance?  
Yes/No:   
5. Have you noticed a change in your hearing ability?  
Yes/No:  
Is yes, is it in both ears, the right ear or the left ear?   
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6.6 Appendix F: Recording Sheet 
Recording Sheet 
Numerical code:  
Otoscopy result:  
Right:  
Left:  
Tympanometry Results:  
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Pure Tone Audiometry Result:  
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Informed Consent Form 
Study Title:  
Automated Audiometry and the SRO Technique in Ototoxicity Monitoring  
The Researcher:  
My name is Wildine Greeff and I am a postgraduate student studying towards my Master’s 
Degree in Audiology at the University of Cape Town. This study will be completed by researchers from 
the University of Cape Town.   
Purpose of the research:  
There are many South Africans that have Multi-Drug Resistant Tuberculosis (MDR-TB). Some 
medication used to treat MDR-TB may damage hearing. That is why each person receiving these MDR-
TB medication needs regular hearing tests. These hearing tests can be long and there are not enough 
audiologists to do these hearing tests on everyone that needs it. With this research I hope to, firstly 
make these hearing tests shorter. Secondly, I want to help each person receiving these MDR-TB 
treatments to be tested often by having computers help test patients if the audiologist is unable to.  
What the research will involve:  
The research that I am doing involves regularly testing the hearing of patients on MDR-TB 
treatment. During the hearing tests, I will: 
• Ask you a few questions about your hearing. 
• Look at the health of your eardrum with a light.  
• Test the middle part of your ear to see if it is working as it should be.   
• Test to see whether you can hear different types of sounds. I will be doing the test myself, 
after a fifteen-minute break, a computer will do the same test again without my help.   
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These tests are not harmful, and the location of the hearing tests will be communicated to 
you. I will be explaining each test before I test you with it. I will show and explain the results to you at 
the end of each test session. Your test results will stay at the hospital. I will be testing you every week 
for a month or until I see a change in the hearing test results (for example, a hearing loss or an ear 
infection). Each test session will take approximately 60 minutes. I will write your follow-up test date 
on this information page that you will need to keep. I will provide counselling to explain the possible 
reason for the change in hearing and refer you back to your doctor and audiologist for further 
management. After this, you need to fill in short questions about the test you preferred (between me 
testing you or the computer testing you). You will then be seen by your audiologist after you have 
completed your part in the study. I will also be looking at your medical records for any information 
that may affect my results (such as other medication that you are on and the results of your first 
hearing test after starting your MDR-TB medication).  
What will happen to your results?  
After you have exited the research study, I will remove your name from the results sheet and 
replace it with a number. I will upload this information to a password protected cloud. I will be the 
only one that knows this password. I will need to keep the hardcopy of your results in a locked cabinet 
in my supervisor’s office for five years. After that I will destroy the hardcopy. I will compare the results 
that I have gotten when I tested you with the results the computer has gotten to see whether the 
results were the same.  
You will get the option of choosing whether you want to receive the results of the study or 
not. If so, please provide your contact details. In addition to you receiving the results, a summary of 
the results will be sent to the University of Cape Town. I will be providing a conference presentation 
about the results and publish an internal report about my research. You contribute to this research by 
expressing your test method preference as explained previously. 
Sharing your results:  
I will need to share your results with your doctor and audiologist if there has been a change 
to your hearing (for example, a hearing loss or an ear infection). This is so that your doctor and/or 
audiologist can manage the change in your hearing so that it does not get worse and affect your 
communication.  
Voluntary participation and right to withdraw from research:  
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It is your decision to be part of the research. You have the right to exit the study at any time. 
You do not need to give a reason for your decision to leave the research. The results that we may 
already have will still be used for the research.   
Risks from the research:  
You may be tired during testing as you will be tested twice with the same type of test so that 
I can compare the results. You will get a fifteen-minute break in between tests. You may feel distressed 
if you discover that there is a change in your hearing. I will provide you with counselling where I will 
explain why this change has happened and what can be done to help prevent this change from 
continuing. I will refer you back to your doctor and audiologist for further management.   
Benefits from this research:  
 You will benefit directly from this research by receiving compensation every time you attend 
a test session at the facility. The research community and, hopefully, South Africa will benefit by this 
research providing evidence for how the computer that does testing for the audiologist has worked to 
help test hearing. They will also benefit by having evidence for a shorter way to test hearing.  
This research has been reviewed and approved by the University of Cape Town’s Faculty of 
Health Sciences Human Research Ethics Committee (UCT’s FHS HREC).  
If you feel (at any stage during this research) that your rights as a participant of this study has 
been undermined/violated, do not hesitate to contact UCT’s FHS HREC on 021 650 3002.  
If you have any question regarding this research, please do not hesitate to ask or contact 
me. The UCT FHS Human Research Ethics Committee can be contacted in case you have any questions 
regarding your rights and welfare as a research participant of this study.  
If you would like to participate in this study, please fill in the consent form attached to this 
letter.  
Kind regards,  
Ms Wildine Greeff, Postgraduate Student  
0796231822, Grfwil003@myuct.ac.za  
__________________  




Ms Vera-Genevey Hlayisi, Research Co-Supervisor and Lecturer  
Vera.hlayisi@uct.ac.za  
University of Cape Town’s Faculty of Health Sciences Human Research Ethics Committee  




INFORMED CONSENT FORM 
Please fill in the following information:  
I, __________________________________________ hereby give consent for my hearing to 
be tested for the postgraduate research project done by Wildine Greeff. I have read and understood 
the above-mentioned information concerning this postgraduate research project. I understand that 
my hearing test results will be used for research purposes in conforming to the Health Professionals 





Witness Signature  
 Date: 
  
  
  
  
